Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Alsaadi et al. [4] 2008 RS 1/1 T1D NR 24 100% (1/1)
100% (1/1)b 		NR NR NR NR
Alsaadi et al. [67] 2008 RS NR/1 T1D NR Up to prosthetic loading NR
0% (0/1)c 		NR NR NR NR
Hasanoglu Erbasar et al. [70] 2019 RS 7/NR T1D NR ≥ 6 85.7% (6/7)
NR 		NR NR 28.6% (2/7)
NR 		71.4% (5/7)
NRd
Overall
T1D - RS: 3 8/2 - NR Mean: 24 87.5% (7/8)
50% (1/2)
Of these: 100% (1/1) early loss 		NR NR 28.6% (2/7)
NR 		71.4% (5/7)
NRd
T1D
+concomitant ADs 		- Irr. None - Irr. Irr. Irr. Irr. Irr. Irr. Irr.

a = weighted mean or median; b = early loss NR; c = late loss NR; d = criteria by Albrektsson et al. [119].
ADs = autoimmune diseases; Irr. = irrelevant; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; RS = retrospective study.